233 related articles for article (PubMed ID: 18793587)
1. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.
Lewis JH; Larrey D; Olsson R; Lee WM; Frison L; Keisu M
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):327-39. PubMed ID: 18793587
[TBL] [Abstract][Full Text] [Related]
2. Hepatic findings in long-term clinical trials of ximelagatran.
Lee WM; Larrey D; Olsson R; Lewis JH; Keisu M; Auclert L; Sheth S
Drug Saf; 2005; 28(4):351-70. PubMed ID: 15783243
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced liver injury in humans: the case of ximelagatran.
Keisu M; Andersson TB
Handb Exp Pharmacol; 2010; (196):407-18. PubMed ID: 20020269
[TBL] [Abstract][Full Text] [Related]
4. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.
Teschke R; Eickhoff A; Schulze J; Danan G
Transl Gastroenterol Hepatol; 2021; 6():51. PubMed ID: 34423172
[TBL] [Abstract][Full Text] [Related]
5. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
[TBL] [Abstract][Full Text] [Related]
6. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
Agnelli G; Eriksson BI; Cohen AT; Bergqvist D; Dahl OE; Lassen MR; Mouret P; Rosencher N; Andersson M; Bylock A; Jensen E; Boberg B;
Thromb Res; 2009; 123(3):488-97. PubMed ID: 18485453
[TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB;
Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258
[TBL] [Abstract][Full Text] [Related]
8. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM).
Nin Chau T; Cheung WI; Ngan T; Lin J; Lee KW; Tat Poon W; Leung VK; Mak T; Tse ML;
Clin Toxicol (Phila); 2011 Jan; 49(1):34-9. PubMed ID: 21114414
[TBL] [Abstract][Full Text] [Related]
9. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
10. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data.
Cheetham TC; Lee J; Hunt CM; Niu F; Reisinger S; Murray R; Powell G; Papay J
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):601-8. PubMed ID: 24920207
[TBL] [Abstract][Full Text] [Related]
11. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
Rochon J; Protiva P; Seeff LB; Fontana RJ; Liangpunsakul S; Watkins PB; Davern T; McHutchison JG;
Hepatology; 2008 Oct; 48(4):1175-83. PubMed ID: 18798340
[TBL] [Abstract][Full Text] [Related]
12. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.
Boudes PF
Contemp Clin Trials; 2006 Oct; 27(5):432-40. PubMed ID: 16769255
[TBL] [Abstract][Full Text] [Related]
13. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
Teschke R; Danan G
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
[TBL] [Abstract][Full Text] [Related]
14. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
15. Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures.
Ainscow EK; Pilling JE; Brown NM; Orme AT; Sullivan M; Hargreaves AC; Cooke EL; Sullivan E; Carlsson S; Andersson TB
Expert Opin Drug Saf; 2008 Jul; 7(4):351-65. PubMed ID: 18613800
[TBL] [Abstract][Full Text] [Related]
16. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
17. Herb induced liver injury by Xianling Gubao Tablets: A case assessed for causality using updated RUCAM and integrated evidence chain.
Li C; Li Y; Bai Z; Wang J; Li G; Xiao X
Chin Herb Med; 2024 Apr; 16(2):301-309. PubMed ID: 38706827
[TBL] [Abstract][Full Text] [Related]
18. RUCAM in Drug and Herb Induced Liver Injury: The Update.
Danan G; Teschke R
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712744
[TBL] [Abstract][Full Text] [Related]
19. Prevention of stroke in patients with atrial fibrillation.
Olsson SB; Halperin JL
Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.
Kindmark A; Jawaid A; Harbron CG; Barratt BJ; Bengtsson OF; Andersson TB; Carlsson S; Cederbrant KE; Gibson NJ; Armstrong M; Lagerström-Fermér ME; Dellsén A; Brown EM; Thornton M; Dukes C; Jenkins SC; Firth MA; Harrod GO; Pinel TH; Billing-Clason SM; Cardon LR; March RE
Pharmacogenomics J; 2008 Jun; 8(3):186-95. PubMed ID: 17505501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
